Acutus Medical Receives Green Signal From FDA To Start AcQBlate Atrial Fibrillation Trial

• The FDA has signed off Investigational Device Exemption (IDE) AcQBlate AF trial for Acutus Medical Inc's (NASDAQ: AFIB) AcQBlate Force Sensing Ablation Catheter and System.

• The trial is expected to enroll 350 subjects and evaluate the system's safety and efficacy in the treatment of both paroxysmal and persistent atrial fibrillation.

• The system is designed to provide consistent, effective therapeutic solutions during cardiac ablation procedures, the AcQBlate Force gold-tipped catheter, and the system shows physicians, in real-time, how much contact force is being applied to the heart during ablations.

• Enrollment for the AcQBlate Force AF trial is expected to begin in the second half of 2021, once participating sites gain necessary institutional review board (IRB) approvals.

• Price Action: AFIB shares are up 7.9% at $15.43 during the premarket session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer

• Timber Pharma Shares Jump As Mid-Stage Skin Disorder Study With TMB-001 Concludes Enrollment Early

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.